Quantitation of androgen receptor gene expression in sporadic breast tumors by real-time RT-PCR: evidence that MYC is an AR-regulated gene - PubMed (original) (raw)
Quantitation of androgen receptor gene expression in sporadic breast tumors by real-time RT-PCR: evidence that MYC is an AR-regulated gene
I Bièche et al. Carcinogenesis. 2001 Sep.
Abstract
Little is known of the function and clinical significance of the androgen receptor (AR) in human breast cancer. Paradoxically, synthetic progestins, such as medroxyprogesterone acetate, are used for second line hormone therapy of breast cancer following tamoxifen failure. A sensitive and accurate assay for AR expression in breast tumors is thus required. Here we have developed and validated a real-time RT-PCR assay to quantify AR gene expression at the mRNA level in a series of 131 patients with unilateral invasive primary breast tumors. AR expression varied widely in tumor tissues (by at least 3 orders of magnitude), being underexpressed in 24/131 (18.3%) and overexpressed in 45/131 (34.4%) relative to normal breast tissues. We observed links (or trends) between AR status and age, menopausal status, Scarff-Bloom-Richardson histopathological grade, lymph node status and estrogen receptor alpha and progesterone receptor status. High AR mRNA levels were negatively linked to MYC gene overexpression (P = 8 x 10(-6)), confirming previous in vitro studies. Our results also suggest a role of the ARA70 gene (which encodes a major AR co-activator) in the AR pathway dysregulation observed in breast cancer. This simple, rapid and semi-automated method will be useful for screening cancer patients for altered AR expression and for predicting the response to androgen therapy in AR-related cancer patients.
Similar articles
- Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy.
Bieche I, Parfait B, Le Doussal V, Olivi M, Rio MC, Lidereau R, Vidaud M. Bieche I, et al. Cancer Res. 2001 Feb 15;61(4):1652-8. Cancer Res. 2001. PMID: 11245479 - Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer.
Bièche I, Parfait B, Laurendeau I, Girault I, Vidaud M, Lidereau R. Bièche I, et al. Oncogene. 2001 Dec 6;20(56):8109-15. doi: 10.1038/sj.onc.1204917. Oncogene. 2001. PMID: 11781824 - Expression and function of androgen receptor coactivators in prostate cancer.
Culig Z, Comuzzi B, Steiner H, Bartsch G, Hobisch A. Culig Z, et al. J Steroid Biochem Mol Biol. 2004 Nov;92(4):265-71. doi: 10.1016/j.jsbmb.2004.10.003. Epub 2004 Dec 19. J Steroid Biochem Mol Biol. 2004. PMID: 15663989 Review. - Differential induction of the androgen receptor transcriptional activity by selective androgen receptor coactivators.
Yeh S, Chang HC, Miyamoto H, Takatera H, Rahman M, Kang HY, Thin TH, Lin HK, Chang C. Yeh S, et al. Keio J Med. 1999 Jun;48(2):87-92. doi: 10.2302/kjm.48.87. Keio J Med. 1999. PMID: 10405524 Review.
Cited by
- Beyond Prostate Cancer: An Androgen Receptor Splice Variant Expression in Multiple Malignancies, Non-Cancer Pathologies, and Development.
Katleba KD, Ghosh PM, Mudryj M. Katleba KD, et al. Biomedicines. 2023 Aug 7;11(8):2215. doi: 10.3390/biomedicines11082215. Biomedicines. 2023. PMID: 37626712 Free PMC article. Review. - ALAN is a computational approach that interprets genomic findings in the context of tumor ecosystems.
Bergom HE, Shabaneh A, Day A, Ali A, Boytim E, Tape S, Lozada JR, Shi X, Kerkvliet CP, McSweeney S, Pitzen SP, Ludwig M, Antonarakis ES, Drake JM, Dehm SM, Ryan CJ, Wang J, Hwang J. Bergom HE, et al. Commun Biol. 2023 Apr 14;6(1):417. doi: 10.1038/s42003-023-04795-1. Commun Biol. 2023. PMID: 37059746 Free PMC article. - In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts.
Passeri T, Dahmani A, Masliah-Planchon J, El Botty R, Courtois L, Vacher S, Marangoni E, Nemati F, Roman-Roman S, Adle-Biassette H, Mammar H, Froelich S, Bièche I, Decaudin D. Passeri T, et al. Front Oncol. 2022 Nov 25;12:960720. doi: 10.3389/fonc.2022.960720. eCollection 2022. Front Oncol. 2022. PMID: 36505864 Free PMC article. - Transcriptome profiling and proteomic validation reveals targets of the androgen receptor signaling in the BT-474 breast cancer cell line.
Vasiliou SK, Filippou PS, Clotet-Freixas S, Soosaipillai A, Batruch I, Viktor Tsianos F, Konvalinka A, Diamandis EP. Vasiliou SK, et al. Clin Proteomics. 2022 May 14;19(1):14. doi: 10.1186/s12014-022-09352-2. Clin Proteomics. 2022. PMID: 35568821 Free PMC article. - ARe we there yet? Understanding androgen receptor signaling in breast cancer.
Michmerhuizen AR, Spratt DE, Pierce LJ, Speers CW. Michmerhuizen AR, et al. NPJ Breast Cancer. 2020 Sep 25;6:47. doi: 10.1038/s41523-020-00190-9. eCollection 2020. NPJ Breast Cancer. 2020. PMID: 33062889 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials